Kumar et al. IMWG Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma. Lancet Oncology 2016; 17(8): e328-e346
“The Hevylite assay is useful in patients with oligo-secretory disease and can overcome limitations associated with monitoring β-migrating monoclonal IgA by electrophoresis”
BCSH Guidelines highlight the usefulness of Hevylite at diagnosis and whilst monitoring treatment response
Bird et al. BCSH Guidelines for the Diagnosis and Management of Multiple Myeloma
“Baseline sFLC concentration may also provide useful prognostic information (Dispenzieri et al. 2008) as may the immunoglobulin heavy/light chain ratios both at diagnosis and following treatment (Ludwig et al. 2010)”
Czech Myeloma Group Guidelines state that Hevylite has utility at low monoclonal immunoglobulin levels
Hájek et al. Suplementum 1 časopisu Transfuze a hematologie (září 2012):Diagnostika a léčba mnohočetného myelomu, Vypracované CMG, Myelomovou sekcí ČHS a SMS
